Immune infiltrate predicts response to αPD1/αCTLA4 but not αPD1 and distinguishes programs of primary resistance in metastatic melanoma
While immune-checkpoint blockade (ICB) has revolutionized treatment of metastatic melanoma, the identification of robust biomarkers to predict the relative efficacy of single versus combination ICB has been challenging. We performed a meta-analysis of eight cohorts of patients treated with anti–PD-1 ( n = 290), anti–CTLA-4 ( n = 175), and combination anti–PD-1/anti–CTLA-4 ( n = 51) with pretreatment tumor sequencing and clinical annotations. Surprisingly, the increased response rate to combination anti–PD-1/anti–CTLA-4 compared to anti–PD-1 monotherapy was observed only in highly immune infiltrated tumors, and not in immune-low tumors. Stratifying tumors by high or low frequency of immune cells also distinguished context-dependent programs of primary resistance to single and combination ICB. Notably, hypoxia-related pathways were enriched in nonresponders to anti–PD-1 ICB in immune-high, but not immune-low, tumors. Using an independent cohort of patients with scRNA-seq data, we observed that correlates of hypoxia were associated with increased stromal tumor receptor-ligand interactions. As proof of concept, selective inhibition of HIF-2α, a component of the hypoxia pathway and highly expressed in endothelial cells and fibroblasts, in combination with anti–PD-1, controlled tumor growth in mouse models of highly immune-infiltrated tumors but not poorly immune-infiltrated tumors. Our work demonstrates how stratification by tumor immune characteristics and clinical features can lead to the rational discovery of novel therapeutic targets.
Authors
- Genevieve Marie Boland (ORCID: https://orcid.org/0000-0002-7522-6173)
- Amy Y. Huang (ORCID: https://orcid.org/0000-0002-6646-6503)
- Emily J. Robitschek (ORCID: https://orcid.org/0000-0002-2771-0155)
- Arlene H. Sharpe (ORCID: https://orcid.org/0000-0002-9736-2109)
- Tyler J. Aprati (ORCID: https://orcid.org/0000-0003-1323-9697)
- Jiekun Yang (ORCID: https://orcid.org/0000-0003-0920-052X)
- Kelly P. Burke (ORCID: https://orcid.org/0000-0003-2187-0147)
- Cora A. Ricker (ORCID: https://orcid.org/0000-0003-1202-5603)
- Marc Glettig (ORCID: https://orcid.org/0000-0002-2512-7740)
- Elizabeth Iannotti Buchbinder (ORCID: https://orcid.org/0000-0002-7979-8953)
- Peter R. Fatouros (ORCID: https://orcid.org/0009-0008-5398-7159)
- Shuyun Xu (ORCID: https://orcid.org/0000-0003-2762-4772)
- Giuseppe Tarantino (ORCID: https://orcid.org/0000-0002-6078-6856)
- Gordon James Freeman (ORCID: https://orcid.org/0000-0002-7210-5616)
- Frank Stephen Hodi (ORCID: https://orcid.org/0000-0001-6825-091X)
- Christine Guo Lian (ORCID: https://orcid.org/0000-0003-4626-1612)
- Doris Fu (ORCID: https://orcid.org/0009-0004-7331-6927)
- Natalie I. Vokes (ORCID: https://orcid.org/0000-0002-3766-5335)
- Jiajia Chen (ORCID: https://orcid.org/0000-0002-5378-6284)
- David Liu (ORCID: https://orcid.org/0000-0003-0346-5033)
- M Kellis (ORCID: https://orcid.org/0000-0001-7113-9630)
- Li‐Lun Ho
- Yiwen He (ORCID: https://orcid.org/0000-0002-3841-4431)
- Kyriaki Galani (ORCID: https://orcid.org/0009-0000-1717-9113)
- Valeria Rosado (ORCID: https://orcid.org/0009-0002-7256-2902)
- Lynn Meiger (ORCID: https://orcid.org/0009-0006-4178-4886)
- Ryan Porter (ORCID: https://orcid.org/0009-0006-6519-8355)
- Jonathan M. Li (ORCID: https://orcid.org/0009-0006-5005-9061)
- Cassia Wang (ORCID: https://orcid.org/0009-0003-2158-0673)
Institutions
- Rutgers, The State University of New Jersey (US)
- Broad Institute (US)
- Brigham and Women's Hospital (US)
- The University of Texas MD Anderson Cancer Center (US)
- Harvard University (US)
- ETH Zurich (CH)
- Massachusetts General Hospital (US)
- Dana-Farber Cancer Institute (US)
- Massachusetts Institute of Technology (US)
Publication Details
- Journal
- Science Advances
- Published
- 2026-11-20
- DOI
- https://doi.org/10.1126/sciadv.aed0035
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- American Association for Cancer Research
- Doris Duke Charitable Foundation
- Cancer Prevention and Research Institute of Texas
- American-Italian Cancer Foundation
- Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
- Barr Foundation
- Society for Immunotherapy of Cancer
- National Institutes of Health
- National Cancer Institute